Company

Autolus Therapeutics plc

Headquarters: London, United Kingdom

Employees: 324

CEO: Dr. Christian Martin Itin Ph.D.

NASDAQ: AUTL -0.16%

Market Cap

$1.09 Billion

USD as of Jan. 1, 2024

Market Cap History

Autolus Therapeutics plc market capitalization over time

Evolution of Autolus Therapeutics plc market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Autolus Therapeutics plc

Detailed Description

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Top 1-year algo backtest: +287.69%

$10,000 in March 2023 would now be $38,769 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Autolus Therapeutics plc has the following listings and related stock indices.


Stock: NASDAQ: AUTL wb_incandescent

Details

Headquarters:

Forest House

58 Wood Lane White City

London, W12 7RZ

United Kingdom

Phone: 44 20 3829 6230